^
Association details:
| Biomarker: | ACTA2 underexpression |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug Class: | PD-L1 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Defining muscle-invasive bladder cancer immunotypes by introducing tumor mutation burden, CD8+ T cells, and molecular subtypes
Published date:
01/02/2021
Excerpt:
Immunotherapy, especially anti-PD-1, is becoming a pillar of modern muscle-invasive bladder cancer (MIBC) treatment...Low expression of ACTA2 was associated with the MIBC survival benefit.
DOI:
10.1186/s41065-020-00165-7
